Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
Pulmonary Arterial HypertensionPulmonary HypertensionRight Heart Dysfunction
Interventions
DEVICE

Aria CV Pulmonary Hypertension System

The Aria CV PH System is indicated for the treatment of adult patients diagnosed with Pulmonary Hypertension in World Health Organization (WHO) Groups I, II, and III who remain symptomatic despite treatment with optimal medical therapy.

Trial Locations (12)

10065

RECRUITING

Cornell University, New York

14627

RECRUITING

University of Rochester, New York

29425

RECRUITING

Medical University of South Carolina, Charleston

43214

RECRUITING

Ohio Health, Columbus

45219

WITHDRAWN

The Christ Hospital, Cincinnati

46260

RECRUITING

St. Vincent Health, Indianapolis

53215

WITHDRAWN

Aurora St Luke's Medical Center, Milwaukee

55435

RECRUITING

University of Minnesota, Minneapolis

55905

RECRUITING

Mayo Clinic, Rochester

90095

RECRUITING

University of California-Los Angeles, Los Angeles

92093

WITHDRAWN

University of California - San Diego, La Jolla

02115

RECRUITING

Brigham and Women's Hospital, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Aria CV, Inc

INDUSTRY

NCT04555161 - Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System | Biotech Hunter | Biotech Hunter